Загрузка...
Development of Novel Diclofenac Analogs Designed to Avoid Metabolic Activation and Hepatocyte Toxicity
[Image: see text] Diclofenac (DCF) is widely used as a nonsteroidal anti-inflammatory drug; however, it is associated with severe liver injury. This adverse reaction is thought to be related to the reactive quinone imine (QI) and acyl glucuronide (AG) metabolites of DCF, but it remains controversial...
Сохранить в:
| Опубликовано в: : | ACS Omega |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Chemical Society
2020
|
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7758955/ https://ncbi.nlm.nih.gov/pubmed/33376898 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsomega.0c04942 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|